EHS
EHS

Aurinia initiates phase 2 trial for voclosporin ophthalmic solution in dry eye

Aurinia Pharmaceuticals is initiating a phase 2 trial of its dry eye syndrome treatment voclosporin ophthalmic solution, according to a press release.
The ocular tolerability of VOS 0.2%, a proprietary nanomicellar formulation, will be evaluated at 4 weeks in comparison to Restasis (cyclosporine ophthalmic emulsion 0.05%, Allergan) in 90 patients with mild to moderate dry eye, the release said.
“Topical calcineurin inhibition is thought to be a mainstay of treatment for dry eye, and based on its unique profile, we believe that VOS has the potential to compete in the multi-billion-dollar
EHS
Back to top button